Johnson & Johnson's immune disorder drug Stelara significantly reduced symptoms of the inflammatory bowel condition Crohn's disease with just one infusion in about half the patients tested, according to the company. The results, released Monday, are the first from multiple late-stage studies - normally the last stage before seeking regulatory approval for Crohn's, which J&J plans to do later this year.